BioNTech settles Covid-19 patent dispute with CureVac
- Shidonna Raven
- Sep 15
- 2 min read
Updated: Sep 16
August 8, 2025
Source: The Guardian
Photo / Image Source: Unsplash,
BioNTech settles Covid-19 patent dispute with CureVac UK’s GSK will receive $370mn and 1% of sales of some vaccines as part of the deal BioNTech plans to acquire CureVac in a deal valued at about $900mn ©
BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the purchase of its German rival. Vaccine makers used messenger RNA, known as mRNA, to discover and develop the Covid-19 shots in record time during the pandemic. But their success quickly descended into battles over who held the key patents on the novel technology, which teaches the body’s immune system to recognise part of the genetic code of the virus.
Under the new deal, GSK will receive $370mn upfront and 1 per cent of all US sales of the Covid-19, flu, and any combination vaccines from the start of 2025. The payments are due to the UK-based drugmaker’s partnership to develop mRNA vaccines with CureVac, another German biotech, which BioNTech plans to acquire in an all-share deal that would give the company an enterprise value of about $900mn.
During the pandemic, GSK contributed its adjuvant — a technology that boosts the efficacy of some vaccines — to other vaccine makers’ shots, but did not develop its own. The company, which has traditionally been a leader in vaccines, then signed a partnership with CureVac to catch up on mRNA technology and create its own Covid-19 jab. Last year, it fully licensed programmes from CureVac, including a Covid-19 vaccine and two flu vaccines in phase 2 trials, and a combination of Covid-19 and flu in phase 1. Since 2022, CureVac has been suing BioNTech, arguing that the rival had been “standing a bit on our shoulders” and infringed vital patents relating to mRNA technology and its partner Pfizer produced the first approved vaccines using the technology, generating billions of dollars in sales. But sales of the Covid-19 jab have been falling as take-up is now often limited to only the oldest and most vulnerable people.
How can such practices impact your health? How Why?
Share the wealth of health with your friends and family by sharing this article with 3 people today.
If this article was helpful to you, donate to the Shidonna Raven Garden and Cook E-Magazine Today. Thank you in advance.
Comments